The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
M. Rask-Andersen,Surendar Masuram,H. Schiöth
2014 · DOI: 10.1146/annurev-pharmtox-011613-135943
Annual Review of Pharmacology and Toxicology · 263 Citations
TLDR
A data set of clinical trial drug-target interactions based on CenterWatch's Drugs in Clinical Trials Database, one of the largest databases of its kind, is developed, identified 475 potentially novel clinical trialDrug targets currently being explored in clinical trials.